SAN FRANCISCO, Jan. 3, 2017 /PRNewswire/ -- Symic Bio, a clinical stage biopharmaceutical company focused on matrix biology developing a new category of therapeutics, today announced that Ken Horne, Chief Executive Officer, will participate in the 2017 East/West CEO Conference on a panel entitled "Global Perspectives on Funding and Innovation."
Conference details are as follows:
Date: Sunday, Jan. 8, 2017
Time: 7:40 a.m. PST
Location: Four Seasons Hotel, San Francisco
About Symic Bio
Symic Bio is a clinical stage biopharmaceutical company focused on matrix biology that is developing a new category of therapeutics. These therapeutics, with potential applications in a wide variety of disease states, are inspired by naturally occurring macromolecules that play key regulatory roles within the extracellular matrix. Symic Bio currently has two clinical candidates, SB-030 for the treatment of critical limb ischemia and SB-061 directed at disease modification in the treatment of osteoarthritis. In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system.
Gitanjali Jain Ogawa
The Trout Group
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/symic-bio-to-participate-in-the-2017-eastwest-ceo-conference-300382429.html
SOURCE Symic Bio